| Nov 12 |
What’s happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA-testing company
|
| Nov 12 |
23andMe GAAP EPS of -$2.32, revenue of $44.07M
|
| Nov 12 |
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 12 |
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
|
| Nov 11 |
23andMe cuts 40% of its workforce, discontinues all therapy programs
|
| Nov 11 |
23andMe reduces workforce by 40%
|
| Nov 11 |
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
|
| Nov 7 |
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
|
| Nov 7 |
23andMe to Report Q2 FY2025 Financial Results
|
